The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of the industry's first liquid qPCR master mixes proven stable for over 12 months at ambient temperatures and shippable with oligos without compromising performance. This breakthrough eliminates the need for refrigeration, freezing, or costly lyophilization (freeze-drying), offering a level of flexibility and convenience not previously available in liquid formats. With superior performance, these new mixes expand Meridian's portfolio of ambient-stable molecular reagents while simplifying logistics, reducing costs, and delivering sustainable solutions for assay developers and high-throughput automation users across all settings — from point-of-care (POC) to centralized labs.

Altesa BioSciences, a clinical stage pharmaceutical company dedicated to preventing and treating rhinovirus infections, one of the leading causes of Chronic Obstructive Pulmonary Disease (COPD) and asthma exacerbations, today announced a partnership with bioMérieux, a world leader in the field of in vitro diagnostics, to utilize the BIOFIRE® SPOTFIRE® respiratory solution as its core point-of-care diagnostics platform at U.S. sites for Altesa’s upcoming Phase 2B clinical trial.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.

Point-of-Care drugs of abuse testing is estimated at $576 million and is anticipated to grow at 2.4% over the next five years.

The most widely used professional and over the counter (OTC) patient self-tests for women’s health are pregnancy and ovulation tests.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care.

The boundaries between the POCT and laboratory-based systems for blood and electrolyte testing are somewhat blurred, and instruments can be used in multiple scenarios.

Cardiovascular disease remains the leading cause of death worldwide. More than half a billion people around the world continue to be affected by cardiovascular diseases, which accounted for 20.5 million deaths in 2021 – close to a third of all deaths globally and an overall increase on the estimated 121 million CVD deaths.

The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of $2.4 million for the development of saliva-based liquid biopsy technologies.

The latest IDF Diabetes Atlas (2025) reports that diabetes affects 589 million adults (20-79 years) around the world in 2024, with over 4 in 10 unaware that they have the condition.